Topical Glaucoma Therapy Is Associated With Alterations of the Ocular Surface Microbiome/Experiment 3

From BugSigDB


Reviewed Marked as Reviewed by KateRasheed on 2025-8-5

Curated date: 2025/08/04

Curator: Anne-mariesharp

Revision editor(s): Anne-mariesharp

Subjects

Location of subjects
United States of America
Host species Species from which microbiome was sampled. Contact us to have more species added.
Homo sapiens
Body site Anatomical site where microbial samples were extracted from according to the Uber Anatomy Ontology
Margin of eyelid , Conjunctiva Free margin of eyelid,Margin of eyelid,margin of eyelid,Conjunctiva,conjunctiva,Conjunctivae,Conjunctivas,Tunica conjunctiva,Wall of conjunctival sac
Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
Glaucoma glaucoma,glaucoma (disease),Glaucoma (disorder),Glaucoma associated with other ocular disorders,Glaucoma associated with other ocular disorders (disorder),Glaucoma associated with other ocular disorders NOS,Glaucoma associated with other ocular disorders NOS (disorder),GLAUCOMA NEC,Glaucoma NOS,Glaucoma NOS (disorder),Glaucoma, NOS,Glaucomas,Other specified forms of glaucoma,Other specified forms of glaucoma (disorder),Other specified glaucoma,Other specified glaucoma NOS,Other specified glaucoma NOS (disorder),Unspecified glaucoma,Glaucoma
Group 0 name Corresponds to the control (unexposed) group for case-control studies
Control subject samples
Group 1 name Corresponds to the case (exposed) group for case-control studies
Patients samples with eyedrops
Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
Samples from glaucoma patients that were treated with eyedrops
Group 0 sample size Number of subjects in the control (unexposed) group
28
Group 1 sample size Number of subjects in the case (exposed) group
20
Antibiotics exclusion Number of days without antibiotics usage (if applicable) and other antibiotics-related criteria used to exclude participants (if any)
3 months

Lab analysis

Sequencing type
16S
16S variable region One or more hypervariable region(s) of the bacterial 16S gene
V3-V4
Sequencing platform Manufacturer and experimental platform used for quantifying microbial abundance
Illumina

Statistical Analysis

Data transformation Data transformation applied to microbial abundance measurements prior to differential abundance testing (if any).
relative abundances
Statistical test
Wald Test
Significance threshold p-value or FDR threshold used for differential abundance testing (if any)
0.05
MHT correction Have statistical tests be corrected for multiple hypothesis testing (MHT)?
Yes
Matched on Factors on which subjects have been matched on in a case-control study
age

Alpha Diversity

Shannon Estimator of species richness and species evenness: more weight on species richness
increased

Signature 1

Reviewed Marked as Reviewed by KateRasheed on 2025-8-5

Curated date: 2025/08/04

Curator: Anne-mariesharp

Revision editor(s): Anne-mariesharp

Source: Table 4, Supplemental Table 1

Description: Significant differentially abundant taxa between patient samples with eyedrops and control subject samples

Abundance in Group 1: increased abundance in Patients samples with eyedrops

NCBI Quality ControlLinks
Aedoeadaptatus coxii
Akkermansia muciniphila
Anaerobutyricum hallii
Anaerococcus vaginalis
Anaerostipes
Anaerostipes hadrus
Bifidobacterium bifidum
Bifidobacterium longum
Blautia
Butyricicoccus
Enterorhabdus
Eubacterium coprostanoligenes
Ezakiella
Faecalibacterium prausnitzii
Flavonifractor plautii
Gluconobacter oxydans
Intestinibacter bartlettii
Lachnoclostridium
Lachnospira
Lachnospira eligens
Lachnospiraceae
Lachnospiraceae bacterium NK4A136
Mediterraneibacter gnavus
Monoglobus
Negativibacillus
Oscillibacter
Oscillospiraceae
Roseburia
Roseburia intestinalis
Roseburia inulinivorans
Rothia mucilaginosa
Ruminococcus bromii
Ruminococcus callidus
[Eubacterium] siraeum
[Ruminococcus] torques
Komagataeibacter rhaeticus/xylinusKomagataeibacter rhaeticus/xylinus
Ruminococcaceae CAG-352Ruminococcaceae CAG-352
Oscillospiraceae NK4A214 groupOscillospiraceae NK4A214 group
Oscillospiraceae UCG-002Oscillospiraceae UCG-002
Clostridia vadin BB60 groupClostridia vadin BB60 group
Blautia obeum/wexleraeBlautia obeum/wexlerae

Revision editor(s): Anne-mariesharp

Signature 2

Reviewed Marked as Reviewed by KateRasheed on 2025-8-5

Curated date: 2025/08/04

Curator: Anne-mariesharp

Revision editor(s): Anne-mariesharp

Source: Table 4, Supplemental Table 1

Description: Significant differentially abundant taxa between patient samples with eyedrops and control subject samples

Abundance in Group 1: decreased abundance in Patients samples with eyedrops

NCBI Quality ControlLinks
Corynebacterium bovis
Corynebacterium kroppenstedtii
Corynebacterium macginleyi
Corynebacterium aurimucosum/pseudogenitalium/tuberculostearicumCorynebacterium aurimucosum/pseudogenitalium/tuberculostearicum
Cutibacterium acnes/avidumCutibacterium acnes/avidum
Bradyrhizobium
Rothia dentocariosa
Blautia coccoides/hansenii/marasmi/productaBlautia coccoides/hansenii/marasmi/producta
Sphingobium yanoikuyae
Lachnospiraceae
Lachnospiraceae A2 groupLachnospiraceae A2 group
Clostridium sensu stricto 1 perfringens/thermophilusClostridium sensu stricto 1 perfringens/thermophilus
Micrococcus aloeverae/luteus/lylae/yunnanensisMicrococcus aloeverae/luteus/lylae/yunnanensis
Lawsonella
Corynebacterium fournieri/mucifaciens/ureicelerivoransCorynebacterium fournieri/mucifaciens/ureicelerivorans
Novosphingobium
Eubacterium ruminantium
Anaerococcus
Bifidobacterium adolescentis/faecale/stercorisBifidobacterium adolescentis/faecale/stercoris
Cutibacterium granulosum
Cutibacterium

Revision editor(s): Anne-mariesharp